E108 692
[8]
Antonarakis ES, Lu C, Luber B, et al. AR-V7 and efficacy of abiraterone (Abi) and enzalutamide (Enza) in castration-resistant prostate can- cer (CRPC): expanded analysis of the Johns Hopkins cohort. J Clin Oncol 2016;34(Suppl):5012.[9]
Steinestel J, Bernemann C, Schrader AJ, Lennerz JK. Reply from authors re: Emmanuel S. Antonarakis, Howard I. Scher. Do patients with AR-V7–positive prostate cancer benefit from novel hormonal therapies? It all depends on definitions. Eur Urol 2017;71:4–6. Unsplicing a conflict. Eur Urol 2017;71:6–7.
Julie Steinestel
a,
*
Christof Bernemann
a
Andres J. Schrader
a
Jochen K. Lennerz
b
a
Clinic of Urology, University Hospital Muenster, Muenster, Germany
b
Massachusetts General Hospital/Harvard Medical School, Boston, MA, USA
*Corresponding author. Clinic of Urology, University Hospital Mu¨ nster,
Albert-Schweitzer-Campus 1, Mu¨ nster 48149, Germany.
Tel.
+49 251 8347442
; Fax:
+49 251 8349739
.
E-mail address:
julie.steinestel@ukmuenster.de(J. Steinestel).
September 7, 2016
E U R O P E A N U R O L O G Y 7 1 ( 2 0 1 7 ) e 1 0 7 – e 1 0 8
e108